October 29, 2020
Centrexion Therapeutics Raises $40.5 Million and Adds Lilly and Exome Asset Management as New Investors
December 3, 2019
Centrexion Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Lead Pipeline Candidate CNTX-4975
November 8, 2019
Centrexion Therapeutics Announces CNTX-4975 Data Presentations at the 2019 American College of Rheumatology Annual Meeting and the 2019 American Academy of Physical Medicine and Rehabilitation Annual Assembly
September 17, 2019
Centrexion Therapeutics Announces Completion of Patient Enrollment in VICTORY-3 Phase 3 Open-Label Clinical Trial of CNTX-4975 in Patients with Moderate-to-Severe Osteoarthritis Knee Pain
September 4, 2019
Centrexion Therapeutics Announces CNTX-4975, CNTX-6970 and CNTX-6016 Data Presentations at PAINWeek 2019 National Conference
July 18, 2019
Centrexion Therapeutics to Present New Positive Clinical Trial Results on Streamlined CNTX-4975 Administration Techniques
June 11, 2019
Centrexion Therapeutics to Announce CNTX-4975 Trial Results at the European League Against Rheumatism’s (EULAR) 2019 Annual European Congress of Rheumatology
June 5, 2019
Centrexion Therapeutics Announces Completion of Patient Enrollment in Pivotal Clinical Trial of Repeat Doses of CNTX-4975 in Patients with Moderate to Severe Osteoarthritis Knee Pain
May 28, 2019
Lilly Announces Licensing Agreement for Non-Opioid Pain Asset from Centrexion Therapeutics
April 29, 2019
Centrexion Therapeutics Announces CNTX-4975 Data Presentations at the 2019 British Society for Rheumatology Annual Conference and Osteoarthritis Research Society International 2019 World Congress
March 27, 2019
Centrexion Therapeutics Announces Publication of Phase 2 Efficacy Data on CNTX-4975 for Treatment of Moderate to Severe Knee Osteoarthritis Pain in Arthritis & Rheumatology
March 7, 2019
Centrexion Therapeutics Announces CNTX-4975 Preclinical and Clinical Data Presentations at the 35th Annual American Academy of Pain Medicine Meeting
December 5, 2018
Centrexion Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 Clinical Trial of CNTX-4975 for the Treatment of Moderate to Severe Knee Osteoarthritis Pain
October 16, 2018
Centrexion Therapeutics Announces Two CNTX-4975 Presentations at the 2018 American College of Rheumatology Annual Meeting
September 24, 2018
Centrexion Therapeutics Appoints Andrew Partridge as Executive Vice President, Chief Commercial Officer
September 6, 2018
Centrexion Therapeutics Announces CNTX-4975 Data Presentation at PAINWeek 2018 National Conference
August 15, 2018
Centrexion Therapeutics Appoints Dan Mendelson to its Board of Directors
July 30, 2018
Centrexion Therapeutics Appoints Financial Executive Nick Harvey as Chief Financial Officer
June 26, 2018
Centrexion Therapeutics Appoints Veteran Healthcare Innovator Joseph R. Swedish to its Board of Directors
April 19, 2018
Centrexion Therapeutics Announces CNTX-4975 and CNTX-6970 Clinical Data Presentations at the 34th Annual American Academy of Pain Medicine Meeting
March 1, 2018
Centrexion Therapeutics to Present CNTX-4975 Clinical Data at the American Academy of Orthopaedic Surgeons 2018 Annual Meeting
February 21, 2018
Centrexion Therapeutics Announces First Patient Dosed in Phase 3 Trial of CNTX-4975 for the Treatment of Moderate to Severe Knee Osteoarthritis Pain
January 16, 2018
Centrexion Therapeutics Announces Fast Track Designation Granted by FDA to CNTX-4975 for Treatment of Knee Osteoarthritis Pain
January 5, 2018
Centrexion Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference
January 2, 2018
Centrexion Therapeutics Raises $67 Million; Launching Phase 3 Program for CNTX-4975 in Knee Osteoarthritis Pain in 2018
October 30, 2017
Centrexion Therapeutics Announces Multiple Data Presentations on CNTX-4975 at the American College of Rheumatology Annual Meeting 2017
September 26, 2017
Centrexion Therapeutics to Present Clinical Data from Pipeline of Chronic Pain Treatments at the 11th Annual Pain and Migraine Therapeutics Summit
August 29, 2017
Centrexion Therapeutics to Present 6-Month Efficacy Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at PAINWeek 2017
July 20, 2017
Centrexion Therapeutics to Present Phase 2b Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Morton’s Neuroma at the American Podiatric Medical Association 2017 Annual Scientific Meeting
July 18, 2017
Centrexion Therapeutics Provides Updates and Advancements for Pipeline of Chronic Pain Treatments
June 26, 2017
Centrexion Therapeutics Names Shawn Tomasello to its Board of Directors
June 13, 2017
Centrexion Therapeutics Announces New 6-Month Data Demonstrating Significant and Durable Pain Relief with CNTX-4975 for Treatment of Moderate to Severe Knee Osteoarthritis Pain
June 7, 2017
Centrexion Therapeutics Announces Oral Presentation of Six Month Efficacy Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at the Annual European Congress of Rheumatology (EULAR 2017)
June 1, 2017
Centrexion Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference
May 25, 2017
Centrexion Therapeutics to Present Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at European Federation of National Associations of Orthopaedics and Traumatology’s 2017 Annual Congress
May 10, 2017
Centrexion Therapeutics to Present Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Morton’s Neuroma and Knee Osteoarthritis at American Pain Society 2017 Annual Scientific Meeting
March 23, 2017
Centrexion Therapeutics to Present Data on CNTX-4975 from the Treatment of Knee Osteoarthritis Pain at IX SIMPAR-ISURA
March 16, 2017
Centrexion Therapeutics to Present Late-Breaking Poster at the 33rd Annual American Academy of Pain Medicine Meeting
February 9, 2017
Centrexion Therapeutics to Present at the 19th Annual BIO CEO & Investor Conference
December 13, 2016
Centrexion Therapeutics Announces Highly Statistically Significant Topline Results from Phase 2b Study of CNTX-4975 in Patients with Knee Osteoarthritis Pain
November 15, 2016
Centrexion Therapeutics Announces Fast Track Designation Granted by FDA to CNTX-4975 for Treatment of Morton’s Neuroma
March 30, 2016
Centrexion Therapeutics Expands Pain Pipeline with Acquisition of Three New Analgesic Candidates from Boehringer Ingelheim